Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2003 Dec 5;313(2):336–342. doi: 10.1016/j.bbrc.2003.11.131

Nucleic acid sequence-based amplification methods to detect avian influenza virus

Lok-Ting Lau a,b, Jill Banks c, Rebecca Aherne c, Ian H Brown c, Natalie Dillon b, Richard A Collins b, Ka-Yun Chan b, Yin-Wan Wendy Fung a,b, Jun Xing b, Albert CH Yu a,b,
PMCID: PMC7111163  PMID: 14684165

Abstract

Infection of poultry with highly pathogenic avian influenza virus (AIV) can be devastating in terms of flock morbidity and mortality, economic loss, and social disruption. The causative agent is confined to certain isolates of influenza A virus subtypes H5 and H7. Due to the potential of direct transfer of avian influenza to humans, continued research into rapid diagnostic tests for influenza is therefore necessary. A nucleic acid sequence-based amplification (NASBA) method was developed to detect a portion of the haemagglutinin gene of avian influenza A virus subtypes H5 and H7 irrespective of lineage. A further NASBA assay, based on the matrix gene, was able to detect examples of all known subtypes (H1–H15) of avian influenza virus. The entire nucleic acid isolation, amplification, and detection procedure was completed within 6 h. The dynamic range of the three AIV assays was five to seven orders of magnitude. The assays were sensitive and highly specific, with no cross-reactivity to phylogenetically or clinically relevant viruses. The results of the three AIV NASBA assays correlated with those obtained by viral culture in embryonated fowl’s eggs.

Keywords: Avian influenza, Haemagglutinin, Nucleic acid sequence-based amplification, NASBA


Influenza A viruses have a segmented genome of single-stranded negative-sense RNA and belong to the family Orthomyxoviridae [1]. They have been isolated from a variety of animals, including humans, pigs, horses, sea mammals, and birds [2]. In humans influenza viruses cause a highly contagious acute respiratory disease that has probably been responsible for epidemic and pandemic disease in humans for centuries [3]. In avian species most influenza virus infections cause mild localized infections of the respiratory and intestinal tract, and the disease is termed low pathogenicity avian influenza (LPAI). Some extremely virulent viruses cause highly pathogenic avian influenza (HPAI) in poultry, a systemic infection in which mortality may be as high as 100%.

All AIVs are type A and can be further subtyped according to the antigenicity of two envelope glycoproteins, haemagglutinin (HA) and neuraminidase (NA). Fifteen subtypes of HA (H1–15) and nine subtypes of NA (N1–9) have been identified to date. Only viruses of H5 and H7 subtypes cause HPAI, although not all viruses of these two subtypes actually cause HPAI [4]. There have been 13 reported outbreaks of HPAI due to subtype H7 and 12 outbreaks due to subtype H5 (counting the four incidents in Hong Kong since 1997 as separate outbreaks) since 1959. In addition, many outbreaks of LPAI infection have occurred from these two subtypes. In the northeast United States, an ongoing outbreak of H7 LPAI has been observed since 1994, primarily in live-bird markets [5]. There is evidence that HPAI viruses arise from LPAI strains after they cross from the aquatic bird reservoir into domestic poultry [6], [7]. In northern Italy, outbreaks of avian influenza due to an H7N1 virus of low pathogenicity occurred in domestic poultry from March to December 1999 when a HPAI virus emerged. In the following months, 13 million birds were affected [8], [9]. In early 2003, an outbreak of highly pathogenic H7N7 in Netherlands (spreading to Belgium and Germany) resulted in the death or culling of about 30 million birds.

In recent years there have been examples of AIVs directly crossing the species barrier to infect humans. In 1996, an avian influenza virus [A/England/268/96 (H7N7)] was isolated from a woman with conjunctivitis [10], and a virus of the same subtype was isolated from a man with infectious hepatitis [11]. The highly pathogenic H7N7 outbreak in the Netherlands of 2003 resulted in one human fatality and approximately 100 other confirmed human AIV infections. The most significant transmission took place in Hong Kong where an outbreak of HPAI subtype H5N1 occurred in chickens resulting in high mortality for infected birds in 1997 [12], [13]. The same virus was then isolated from 18 individuals in Hong Kong, six of whom died. This was the first reported instance of an avian influenza virus H5N1 directly crossing the species barrier and infecting humans. Epidemiological studies indicated that 3.7% of healthcare workers who came into contact with the infected patients had antibodies against H5N1 compared with 0.7% of healthcare workers who had no documented contact [14]. In addition, 3% of government workers instructed to carry out the poultry culling and cleanup operation were subsequently found to have antibodies to H5N1 [15], and a further 10% of poultry workers were also found to be seropositive with respect to H5N1 [15]. HPAI infections of the H5N1 subtype subsequently recurred in Hong Kong in May 2001, February and April 2002, and December 2002/January 2003. In February 2003, an H5N1 virus genetically distinct from that isolated from humans in 1997 was isolated from two people who had visited Fujian province in Mainland China. Of these confirmed infections one person died. Thus, H5N1 viruses in Hong Kong and China represent a continued economic and public health risk with the potential for a pandemic strain to arise in this area [16].

The potential for other subtypes of AIV to infect humans must always be considered and this has been demonstrated by the direct transfer of AIV H9N2 to humans on at least two separate occasions [17], [18], emphasizing the need for continued research into rapid diagnostic tests for influenza. Several techniques are used to isolate, detect, and identify influenza viruses. Viral culture in embryonated fowl’s eggs is the currently accepted and the most widely used standard for the laboratory diagnosis of influenza [3]. This method is very sensitive but also labor-intensive and time-consuming (2–10 days). By comparison, viral antigen detection techniques (enzyme-linked immunoassay and immunofluorescence) are relatively rapid and straightforward [19], [20]. However, they are significantly less sensitive and specific than isolation in embryonated eggs. Molecular techniques, such as PCR [21], [22], are highly sensitive and allow rapid diagnosis of influenza infection; however, these techniques may require additional time for result confirmation by viral culture or ELISA. Real-time PCR assays for influenza A and B [23] and subtypes H1, H3, H5, and H7 [24], [25] have been reported.

Nucleic acid sequence-based amplification (NASBA) methods based on the amplification of the nucleoprotein gene for influenza A viruses and the HA gene of the H5 Eurasian lineage have been described [26], [27], [28]. A preliminary study of a NASBA assay to detect avian influenza subtype H7 has also been made [29]. NASBA is a transcription-based amplification system specifically designed for the detection of RNA targets [30] and allows the continuous amplification of nucleic acids in a single mixture at a single temperature [31].

In this paper, we describe a rapid detection method for all subtypes of influenza A viruses (NASBA-AIV), in addition to H5-specific (NASBA-H5) and H7-specific (NASBA-H7) detection methods using NASBA technology. The NASBA-AIV assay is able to detect influenza A virus H1–H15 subtypes, while NASBA-H7 can detect the Eurasian and North American lineages (also the Australian sub-lineage) and NASBA-H5 detects most lineages. The sensitivity of the different NASBA assays with viral culture in embryonated fowl’s eggs is also compared.

Materials and methods

Viruses. In this study, all viruses were derived from the virus repository of the EU/OIE/FAO international reference laboratory for AI at the Veterinary Laboratories Agency, New Haw, Addlestone, Weybridge, Woking, Surrey, UK (Table 1, Table 2, Table 3 ). Representative strains were derived principally from avian hosts to include H subtypes 1–15 but also included some viruses from mammalian hosts. Several other clinically relevant viral pathogens were used for specificity testing (listed in Table 4, Table 5, Table 6 ).

Table 1.

Sequence of primers and probes used in this study

Virus specificity Name Sequence (5–3) Sequence coordinates

H5 H5-ECL GAT GCA AGG TCG CAT ATG AG GT GA(C/T) AAT GAA TG(C/T) ATG GAA 1457–1476a
H5-T7 AAT TCT AAT ACG ACT CAC TAT AGG GAG AAG G CCA IAA AGA (C/T)AG ACC AGC TA 1653–1634a
H5-CP Biotin-GC(A/G) AGT TC(C/T) CTA GCA CTG GCA AT 1606–1628a



H7 H7-ECL GAT GCA AGG TCG CAT ATG AG AGA (A/T)CA GGA TCT TCA TTC TAT GCA GAG (A/C)TG AA 445–476b
H7-T7 AAT TCT AAT ACG ACT CAC TAT AGG G AGA AGG TIA CTG TGT CAT T(A/G)G 752–743b
H7-CP-1 Biotin-G(A/G)C CAC AAG TGA ATG G(A/C/T)C AAT
H7-CP-2 Biotin-GAC CAC (A/C)AG TAA ATG GTC AGT 686–706b



A
AIV-ECL GAT GCA AGG TCG CAT ATG AG CTT CTA ACC GAG GTC GAA ACG TA 25–47c
AIV-T7 AAT TCT AAT ACG ACT CAC TAT AGG GAG AAG G A(A/G)G GCA TT(C/T) TGG ACA AA(G/T) CGT CTA 269–246c
AIV-CP
Biotin-CCG TCA GGC CCC CTC AAA GCC GA
64–86c

I, inosine.

Underscore indicates the T7 DNA-dependent RNA polymerase binding sequence.

Bold type indicates the sequence complementary to the ECL detection probe.

a

A/Mallard duck/Pennsylvania/10218/84 (H5N2) haemagglutinin gene (AF100180).

b

A/turkey/Italy/5074/99 (H7N1) haemagglutinin gene (AF364171).

c

A/Duck/Hong Kong/552/79 (H9N2) matrix gene (AF523495).

Table 2.

Sensitivity of NASBA-AIV and NASBA-H7 assays in detecting avian influenza H7N1 virus

Dilution
A/chicken/Italy/1081/99 (H7N1)a
NASBA-AIV
NASBA-H7
ECL signal
Result
ECL signal
Result
10−1 1,328,502 Positive 335,510 Positive
10−2 1,206,822 Positive 295,700 Positive
10−3 1,486,492 Positive 288,692 Positive
10−4 1,409,444 Positive 289,765 Positive
10−5 1,216,368 Positive 58,448 Positive
10−6 1,181,705 Positive 89,067 Positive
10−7 538 Negative 122 Negative
10−8 342 Negative 52 Negative
10−9 352 Negative −115 Negative
10−10 288 Negative 69 Negative
IRS 54,715 NA 49,415 NA
Cut-off value (0.025 × IRS) 1367 NA 1235 NA

IRS, instrument reference solution.

NA, not applicable.

a

108.92 EID50/ml.

Table 3.

Sensitivity of NASBA-AIV and NASBA-H5 assays in detecting avian influenza virus H5N3

Dilution
A/pekin duck/Singapore-Q/F119/3/97 (H5N3)a
NASBA-AIV
NASBA-H5
ECL signal
Result
ECL signal
Result
10−1 715,693 Positive 1,323,942 Positive
10−2 726,276 Positive 1,283,673 Positive
10−3 666,961 Positive 1,339,277 Positive
10−4 782,306 Positive 1,085,974 Positive
10−5 800,196 Positive 1,437,995 Positive
10−6 226 Negative 1,965,036 Positive
10−7 202 Negative 10,000,001b Positive
10−8 277 Negative 65 Negative
10−9 180 Negative 162 Negative
10−10 232 Negative 269 Negative
IRS 45,712 NA 44,787 NA
Cut-off value (0.025 × IRS) 1142 NA 1120 NA

IRS, instrument reference solution

NA, not applicable.

a

108.92 EID50/ml.

b

Upper limit of detection.

Table 4.

Specificity of NASBA-AIV assay in detecting subtypes of avian influenza virus and other clinically relevant pathogens

Sample
HA subtype
NASBA
ECL signal
Result
A/Bayern/7/95 H1 637,166 Positive
A/swine/England/195852/92 H1 744,731 Positive
A/Singapore/1/57 H2 1,056,667 Positive
A/duck/Taiwan/17.2-35-2/98 H2 828,145 Positive
A/Sydney/5/97 H3 834,293 Positive
A/budgerigar/China/2873/V00 H3 843,635 Positive
A/duck broiler/Malaysia/F1110702 H3 979,793 Positive
A/duck/Taiwan/22/98 H4 1,427,384 Positive
A/mallard/England/B871/9/96 H4 1,430,347 Positive
A/chicken/South Africa/1050/94 H5 993,027 Positive
A/goose/Italy/1/92 H5 1,308,032 Positive
A/pekin duck/Singapore-Q/F119/3/97 H5 1,310,023 Positive
A/chicken/RSA/01 H6 950,113 Positive
A/turkey/Canada/Ontario/98 H6 1,177,148 Positive
A/shearwater/E.Australia/1/72 H6 997,015 Positive
A/turkey/Germany/R81/99 H6 901,868 Positive
A/ostrich/SA/1609/91 H7 1,309,856 Positive
A/psittacine/Italy/2/91 H7 755,780 Positive
A/equine/Prague/1/56 H7 1,204,701 Positive
A/turkey/Ontario/6118/68 H8 992,758 Positive
A/quail/UAE/369-1642/02 H9 1,343,281 Positive
A/chicken/Pakistan/5/99 H9 1,155,994 Positive
A/shell duck/RSA/145/2/98 H10 886,497 Positive
A/mandarin duck/Singapore/F64/7/93 H10 10,000,001a Positive
A/duck/MEM546/74 H11 88,616 Positive
A/white fronted goose faeces/England/01 H11 10,000,001a Positive
A/duck/Alberta/60/76 H12 1,027,528 Positive
A/gull/Medina/204/77 H13 689,134 Positive
A/mallard/Gurjev/263/82 H14 822,846 Positive
A/shearwater/Australia/79 H15 729,580 Positive
Herpes (11T) 1994 NA 77 Negative
Canary Pox 1997 NA 68 Negative
Parvovirus (GPV) NA -22 Negative
Picornavirus (IAE) 1995 NA 4 Negative
Pneumonia (APV F83) Subtype A NA 74 Negative
Reovirus (S1133) NA -239 Negative
Rotavirus (353/87) NA 21 Negative
Coronavirus (793/B) 1991 NA 50 Negative
Adenovirus (CELO) NA 86 Negative
Influenza B Hawaii 10/01 NA 146 Negative
Influenza C 67 NA 121 Negative
Negative control (water) NA 215 Negative
Instrument Reference Solution NA 49,436 NA
Cut-off limit (0.025 × IRS) NA 1235 NA

NA, not applicable.

a

Upper limit of detection.

Table 5.

Specificity of NASBA-H7 assay in detecting distinct lineages of influenza virus and clinically relevant pathogens

Sample
HA subtype
NASBA
ECL signal
Result
A/ostrich/SA/1609/91 H7N1 488,880 Positive
A/psittacine/Italy/2/91 H7N2 606,191 Positive
A/turkey/N. Ireland/VF-1545 C5/98 H7N7 270,511 Positive
A/turkey/England/262/79 H7N3 99,776 Positive
A/ostrich/RSA/W-4/96 H7N7 370,427 Positive
A/blackbird/Singapore/F92/9/94 H7N1 256,342 Positive
A/bird/Pakistan/447/95 H7N3 372,163 Positive
A/equine/Prague/1/56a H7N7 188 Negative
A/chicken/Bendigo/Victoria/85 H7N7 86,424 Positive
A/chicken/Pakistan/5/99 H9 140 Negative
A/chicken/Pakistan/3/99 H9 129 Negative
A/chicken/Korea/25232-006/96 H9 161 Negative
A/Bayern/7/95 H1 121 Negative
A/Singapore/1/57 H2 118 Negative
A/chicken/RSA/01 H6 193 Negative
A/duck/Singapore-Q/F119-3/97 (H5N3) H5 121 Negative
Herpes (11T) 1994 NA −81 Negative
Canary Pox 1997 NA 114 Negative
Parvovirus (GPV) NA 66 Negative
Picornavirus (IAE) 1995 NA 81 Negative
Pneumonia (APV F83) subtype A NA 124 Negative
Reovirus (S1133) NA 89 Negative
Rotavirus (353/87) NA 155 Negative
Coronavirus (793/B) 1991 NA 100 Negative
Adenovirus (CELO) NA 110 Negative
Instrument Reference Solution NA 51,764 NA
Cut-off limit (0.025 × IRS) NA 1294 NA

NA, not applicable.

a

This reference strain was not detected by the NASBA-H7 assay.

Table 6.

Specificity of NASBA-H5 assay in detecting distinct lineages of influenza virus and clinically relevant pathogens

Sample
HA subtype
NASBA
ECL signal
Result
A/ostrich/Zimbabwe/4066/95 H5N2 1,418,518 Positive
A/chicken/South Africa/1050/94 H5N9 1,959,125 Positive
A/tern/South Africa/61 H5N3 1,389,904 Positive
A/pekin duck/Malaysia/F59/4/98 H5N2 1,322,112 Positive
A/chicken/Italy/367/97 H5N2 1,313,721 Positive
A/chicken/South Africa/1050/94 H5N9 1,931,494 Positive
A/chicken/Italy/RA9097/98 H5N2 10,000,001a Positive
A/turkey/England/50-92/91 H5N1 949,321 Positive
A/ostrich/Denmark/72420/96 pool 2 H5N2 1,044,893 Positive
A/goose/Italy/1/92 H5N2 1,733,398 Positive
A/duck/Singapore-Q/F119-3/97 H5N3 710,641 Positive
A/Bayern/7/95 H1 −166 Negative
A/duck/Taiwan/17.2-35-2/98 H2 105 Negative
A/duck broiler/Malaysia/F1110702 H3 139 Negative
A/shearwater/E.Australia/1/72 H6 152 Negative
A/bird/Pakistan/447/95 H7 129 Negative
A/chicken/Pakistan/5/99 H9 563 Negative
Herpes (11T) 1994 NA 149 Negative
Canary Pox 1997 NA 161 Negative
Parvovirus (GPV) NA 109 Negative
Picornavirus (IAE) 1995 NA 121 Negative
Pneumonia (APV F83) Subtype A NA 88 Negative
Reovirus (S1133) NA 146 Negative
Rotavirus (353/87) NA 122 Negative
Coronavirus (793/B) 1991 NA 101 Negative
Adenovirus (CELO) NA 135 Negative
Instrument Reference Solution NA 43,316 NA
Cut-off limit (IRS × 0.025) NA 1082 NA

NA, not applicable.

a

Upper limit of detection

Embryo titration. Serial 10-fold dilutions (10−2–10−9) of virus were prepared in virus dilution media. For each dilution, 0.1 ml virus-containing medium was inoculated into the allantoic cavity of embryonated fowls’ eggs (n=4–6). After 72 h of incubation at 37 °C, the eggs were chilled and harvested individually and the undiluted allantoic fluids were tested for HA activity [32]. The ELD50 per ml was calculated using the method of Karber [33]. The egg infectious dose is a measure of viral infectivity where the EID50 is the smallest amount of virus capable of initiating infection in 50% of the embryonated fowls’ eggs [34].

Design of primers and probes. The influenza A subtype H1–H15 amplification primers and capture probe were derived after comparison of the conserved sequences of the matrix protein (M) gene obtained from viruses of avian, human, swine, and equine origin. The conserved sequences were selected by sequence alignment of more than 300 M gene sequences retrieved from the GenBank database (National Center of Biotechnology Information, NCBI). Sequence alignments were performed using CLUSTALX software [35]. To further subtype avian influenza viruses using NASBA, we designed H5- and H7-specific amplification primers and capture probes, each based on the conserved sequences of the haemagglutinin genes of these subtypes. Over 100 haemagglutinin gene sequences were retrieved from GenBank for each subtype of avian, human, swine, and equine origin. The H5-ECL and H7-ECL amplification primers each contain two degenerate nucleotides resulting in a mixture of four possible oligonucleotide sequences (Table 1). The H5-T7 and H7-T7 amplification primers each contain two degenerate nucleotides, including inosine, resulting in a mixture of two possible oligonucleotide sequences. The AIV-T7 amplification primer contains three degenerate nucleotides resulting in a mixture of eight possible sequences. The H5-CP capture probe contains two degenerate nucleotides resulting in a mixture of four possible sequences. Two different H7-CP capture probes were designed. H7-CP-1 contains two degenerate nucleotides, producing six possible sequences, while H7-CP-2 contains a single degenerate nucleotide resulting in two possible H7-CP-2 sequences, respectively. The amplification primer and capture probe sequences for each subtype assay are shown in Table 1.

RNA extraction and amplification. RNA was extracted using the RNeasy kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. Briefly, 0.4 ml of allantoic fluid was mixed with 0.4 ml RLT buffer. To this, 0.4 ml of 70% ethanol was added and the entire sample was applied to an RNeasy spin column. The spin column was washed once with 0.7 ml RW1 buffer and twice with 0.5 ml RPE buffer. RNA was eluted in 50 μl nuclease-free water and subjected to amplification reaction using the NASBA method. Briefly, extracted RNA (5 μl) was added to 10 μl amplification mixture according to the protocol of the Basic Kit Amplification Module (bioMérieux bv, Boxtel, Netherlands), followed by incubation at 65 °C for 5 min, and cooling to 41 °C for 5 min. Once cool, 5 μl enzyme mix (containing RNase-H, T7 RNA polymerase, AMV-RT, BSA) was added and the reaction mixture was incubated for 90–120 min at 41 °C for isothermal amplification of RNA.

Signal detection. Detection reagents were prepared by vortex mixing a suspension comprising biotinylated influenza A virus oligonucleotide capture probes bound to streptavidin-coated paramagnetic beads until an opaque solution was formed, as described in the manufacturer’s protocol (bioMérieux). The bead-oligo suspension (10 μl) and 10 μl ruthenium-labeled electrochemiluminescent (ECL) probe were mixed and this mixture (20 μl) was added to 5 μl of the NASBA product and incubated for 30 min at 41 °C. Finally, ECL signal detection was performed in the NucliSens ECL Reader (bioMérieux) according to the manufacturer’s protocol.

Results

Sensitivity of NASBA compared with culture in embryonated fowl’s eggs

The detection limit of the NASBA/ECL and embryonated egg culture methods was examined using 10-fold serial dilutions of H7N1 (for NASBA-AIV and NASBA-H7) and H5N3 virus preparations (for NASBA-AIV and NASBA-H5). The results are summarized in Table 2, Table 3, respectively. Both the NASBA-AIV and NASBA-H7 methods were able to detect the H7N7 subtype at a level of 106-fold dilution (i.e., 102.92 EID50/ml). The NASBA-AIV method could detect the H5N3 subtype at a level of 105-fold dilution (i.e., 103.92 EID50/ml), whilst the NASBA-H5 method detected the H5N3 subtype after 107-fold dilution (101.92 EID50/ml). For both H7N7 and H5N3, the viral culture method was able to routinely detect virus after 107-fold dilution (data not shown).

Specificity of NASBA

The specificity of the NASBA-AIV, NASBA-H7, and NASBA-H5 assays was examined with influenza A virus subtypes H1–15 obtained from widely varying geographic locations and times. Other phylogenetically related viruses containing haemagglutinin-like molecules and clinically relevant pathogens were also examined (Table 4). The NASBA-AIV assay was able to detect representative strains of all 15 subtypes of influenza A virus, and no false positive signals were observed with other viral pathogens. The NASBA-H7 assay detected all the H7 reference strains with the exception of A/equine/Prague/1/56 (Table 5). No false positive signals were observed with other viral pathogens or influenza A viruses of subtypes other than H7. Similarly, the NASBA-H5 assay detected all H5 reference strains (Table 6). Again, no false positive signals were observed with other viral pathogens or influenza A viruses of subtypes other than H5.

Discussion

The AIV assays described here are the first NASBA-based systems capable of rapidly detecting avian influenza H1–H15, H5, and H7 subtypes, irrespective of lineage. It is not intended to compare these NASBA-based methods with other technologies, for example real-time PCR, which have been described elsewhere [24], [25], [26]. The economic consequences of avian influenza, as evidenced in the 2003 outbreak of HPAI H7N7 in the Netherlands, demand a rapid, sensitive, and accurate diagnostic test be readily available. The NASBA-H5 assay described here was previously evaluated using tissue samples (viscera and blood) from chickens experimentally infected with highly pathogenic A/chicken/Hong Kong/1000/97 (H5N1) [28]. The samples gave positive results with the NASBA H5-specific primers [28]. In other studies conducted in our laboratories, cloacal and tracheal samples collected from a dead chicken infected with HPAI subtype H5N1 during an outbreak in Hong Kong in 2002 were examined using the NASBA-H5 assay. Freshly extracted RNA from the cloacal and tracheal samples generated positive results (data not shown). In addition, the NASBA-H5 assay has also utilized avian influenza strains propagated in embryonated fowl’s eggs. Therefore, the NASBA-H5 assay is an efficient method for the direct amplification of viral nucleic acid from both tissue and cultured samples.

NASBA is a continuous isothermal reaction in which a thermal cycler is not required. The NASBA assays described here are rapid molecular techniques for the detection of influenza A virus (NASBA-AIV), subtype H7 (NASBA-H7), and subtype H5 (NASBA-H5) in veterinary samples. Using these assays, an accurate identification of influenza A and subtype H7 or H5 can be made within 6 h. The amplification primers and capture probes are specific to AIV, H7 or H5, and do not cross-react with other haemagglutinin subtypes, phylogenetically related viruses containing haemagglutinin-like molecules, or other clinically relevant pathogens (Table 4, Table 5, Table 6).

Without the need for thermal denaturation for DNA strand separation, as required by conventional PCR, the NASBA assay has the advantage of being able to amplify specific single-stranded RNA target sequences in the presence of genomic DNA contaminants [30]. NASBA/ECL is especially suitable for the detection of RNA viruses, such as influenza, foot-and-mouth disease virus, dengue fever virus, human immunodeficiency virus, and cytomegalovirus, among many others [27], [29], [36], [37], [38], [39]. As the end-product of the NASBA reaction is RNA, which tends to be unstable under normal environmental conditions, the possibility of carryover contamination of equipment from previous experiments is minimized. The NASBA assay, like other nucleic acid-based technologies, has the ability to detect whole infectious particles in addition to partially degraded, non-infectious or mis-packaged virions [25].

The dynamic range of the NASBA/ECL assays was at least five orders of magnitude for NASBA-AIV and at least seven orders of magnitude for NASBA-H5 and NASBA-H7. The NASBA/ECL assays were 10- to 1000-fold more sensitive than commercially available antigen-capture immunoassay and more sensitive than conventional polymerase chain reaction (PCR) methods (data not shown). PCR can amplify DNA greater than 1×107-fold while NASBA can amplify RNA 1×109-fold [31]. Using H7N1 or H5N3 RNA extracts as targets for amplification, the NASBA-AIV, H7, and H5 were comparable in sensitivity with egg culture, which is the currently accepted “gold standard” for virus detection. The NASBA/ECL detection system is highly automated, resulting in fewer handling errors and contributing to an increase in sensitivity and specificity. The target-specific capture probes and generic ECL detection probes hybridize with the complementary amplified target molecules, thus increasing assay specificity during the detection stage. NASBA/ECL has a relatively high throughput, as many as 50 samples can be processed in the ECL reader at the same time. Therefore, it may be a suitable assay to use for routine screening methods, such as in cross-border or poultry market surveillance operations involving analysis of multiple samples simultaneously. The requirements for sample format are extremely robust and swabs taken from cages, work surfaces, clothing, utensils, and litter are suitable for analysis as are tissue samples taken from suspect animals or products from in vitro amplification. This extends the use of the NASBA/ECL method to monitor decontaminated premises or equipment prior to re-stocking with livestock

The NASBA-AIV, NASBA-H5, and NASBA-H7 assays could readily give expected results for certain avian influenza virus subtypes, except in one case that the NASBA-H7 assay failed to detect one particular H7 subtype sample, A/equine/Prague/1/56 (H7N7) (Table 5). The same sample was analysed using the NASBA-AIV assay and yielded a positive result (Table 4). Thus, the failure of the NASBA-H7 assay with respect to this sample was not due to sample degradation. Further analysis of the A/equine/Prague/1/56 H gene sequence (GenBank, X62552) indicated that the H7 amplification primers and capture probe contain several mismatches, probably resulting in a low-efficiency amplification and signal detection for this particular subtype.

The Instrument Reference Solution (IRS), used to monitor the stability of the ECL reader, typically produced ∼30,000–50,000 arbitrary ECL reader units. The negative controls generated very low ECL signals (less than a few hundred ECL units). The cut-off limit was defined as IRS × 0.025 and was further calibrated before each experiment using at least five known negative samples. All the positive reference strains used in this study generated ECL signals greatly exceeding the cut-off limit.

In summary, NASBA/ECL assays for influenza A virus, subtype H7, and subtype H5 have been developed. These assays are comparable in sensitivity to embryonated fowl’s eggs for culture. The rapid assay can generate results within a few hours and may be a suitable alternative to isolation in embryonated eggs (which can take weeks) for the routine screening of poultry or other birds for the presence of influenza A virus.

Acknowledgements

We acknowledge the technical assistance from Mr. Lung Sang Ko. This work was supported by a University-Industry Collaboration Programme Grant (UIM44) from the Innovation and Technology Fund administered by the Innovation and Technology Commission, Commerce, Industry and Technology Bureau of the Hong Kong SAR Government. Any opinions, findings, conclusions or recommendations expressed in this material (or by members of the project team) do not reflect the views of the Government of the Hong Kong SAR or the Commerce, Industry and Technology Bureau.

References

  • 1.Swayne D.E., Suarez D.L. Highly pathogenic avian influenza. Rev. Sci. Tech. 2000;19:463–482. doi: 10.20506/rst.19.2.1230. [DOI] [PubMed] [Google Scholar]
  • 2.Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992;56:152–179. doi: 10.1128/mr.56.1.152-179.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cox N.J., Subbarao K. Influenza. Lancet. 1999;354:1277–1282. doi: 10.1016/S0140-6736(99)01241-6. [DOI] [PubMed] [Google Scholar]
  • 4.Alexander D.J., Brown I.H. Recent zoonoses caused by influenza A viruses. Rev. Sci. Tech. 2000;19:197–225. doi: 10.20506/rst.19.1.1220. [DOI] [PubMed] [Google Scholar]
  • 5.Suarez D.L., Garcia M., Latimer J., Senne D., Perdue M. Phylogenetic analysis of H7 avian influenza viruses isolated from the live bird markets of the northeast United States. J. Virol. 1999;73:3567–3573. doi: 10.1128/jvi.73.5.3567-3573.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rohm C., Horimoto T., Kawaoka Y., Suss J., Webster R.G. Do haemagglutinin genes of highly pathogenic avian influenza viruses constitute unique phylogenetic lineages? Virology. 1995;209:664–670. doi: 10.1006/viro.1995.1301. [DOI] [PubMed] [Google Scholar]
  • 7.Banks J., Speidel E.C., McCauley J.W., Alexander D.J. Phylogenetic analysis of H7 haemagglutinin subtype influenza A viruses. Arch. Virol. 2000;145:1047–1058. doi: 10.1007/s007050050695. [DOI] [PubMed] [Google Scholar]
  • 8.Banks J., Speidel E.C., Moore E., Plowright L., Piccirillo A., Capua I., Cordioli P., Fioretti A., Alexander D.J. Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy. Arch. Virol. 2001;146:963–973. doi: 10.1007/s007050170128. [DOI] [PubMed] [Google Scholar]
  • 9.Capua I., Mutinelli F., Pozza M.D., Donatelli I., Puzelli S., Cancellotti F.M. The 1999–2000 avian influenza (H7N1) epidemic in Italy: veterinary and human health implications. Acta Trop. 2002;83:7–11. doi: 10.1016/s0001-706x(02)00057-8. [DOI] [PubMed] [Google Scholar]
  • 10.Kurtz J., Manvell R.J., Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996;348:901–902. doi: 10.1016/S0140-6736(05)64783-6. [DOI] [PubMed] [Google Scholar]
  • 11.Campbell C.H., Webster R.G., Breese S.S., Jr. Fowl plague virus from man. J. Infect. Dis. 1970;122:513–516. doi: 10.1093/infdis/122.6.513. [DOI] [PubMed] [Google Scholar]
  • 12.Cauthen A.N., Swayne D.E., Schultz-Cherry S., Perdue M.L., Suarez D.L. Continued circulation in China of highly pathogenic avian influenza viruses encoding the hemagglutinin gene associated with the 1997 H5N1 outbreak in poultry and humans. J. Virol. 2000;74:6592–6599. doi: 10.1128/jvi.74.14.6592-6599.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.K.Y. Yuen, P.K.S. Chan, M. Peiris, D.N.C. Tsang, T.L. Que, K.F. Shortridge, P.T. Cheung, W.K. To, E.T.F. Ho, R. Sung, A.F.B. Cheng, members of the H5N1 study group, Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus, Lancet 351 (1998) 467–471 [DOI] [PubMed]
  • 14.Buxton Bridges C., Katz J.M., Seto W.H., Chan P.K., Tsang D., Ho W., Mak K.H., Lim W., Tam J.S., Clarke M., Williams S.G., Mounts A.W., Bresee J.S., Conn L.A., Rowe T., Hu-Primmer J., Abernathy R.A., Lu X., Cox N.J., Fukuda K. Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong. J. Infect. Dis. 2000;181:344–348. doi: 10.1086/315213. [DOI] [PubMed] [Google Scholar]
  • 15.Bridges C.B., Lim W., Hu-Primmer J., Sims L., Fukuda K., Mak K.H., Rowe T., Thompson W.W., Conn L., Lu X., Cox N.J., Katz J.M. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997–1998. J. Infect. Dis. 2002;185:1005–1010. doi: 10.1086/340044. [DOI] [PubMed] [Google Scholar]
  • 16.Hoffmann E., Stech J., Leneva I., Krauss S., Scholtissek C., Chin P.S., Peiris M., Shortridge K.F., Webster R.G. Characterization of the influenza A virus gene pool in avian species in Southern China: was H6N1 a derivative or a precursor of H5N1? J. Virol. 2000;74:6309–6315. doi: 10.1128/jvi.74.14.6309-6315.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Guo Y., Li J., Cheng X. Discovery of men infected by avian influenza A (H9N2) virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1999;13:105–108. [PubMed] [Google Scholar]
  • 18.Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., Orr W.K., Shortridge K.F. Human infection with influenza H9N2. Lancet. 1999;354:916–917. doi: 10.1016/s0140-6736(99)03311-5. [DOI] [PubMed] [Google Scholar]
  • 19.Boivin G., Hardy I., Kress A. Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA Test) in comparison with cell culture and reverse transcription-PCR. J. Clin. Microbiol. 2001;39:730–732. doi: 10.1128/JCM.39.2.730-732.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kaiser L., Briones M.S., Hayden F.G. Performance of virus isolation and Directigen® Flu A to detect influenza A virus in experimental human infection. J. Clin. Virol. 1999;14:191–197. doi: 10.1016/s1386-6532(99)00058-x. [DOI] [PubMed] [Google Scholar]
  • 21.Ellis J.S., Fleming D.M., Zambon M.C. Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J. Clin. Microbiol. 1997;35:2076–2082. doi: 10.1128/jcm.35.8.2076-2082.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Magnard C., Valette M., Aymard M., Lina B. Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. J. Med. Virol. 1999;59:215–220. doi: 10.1002/(sici)1096-9071(199910)59:2<215::aid-jmv15>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  • 23.Van Elden L.J.R., Nijhuis M., Schipper P., Schuurman R., van Loon A.M. Simultaneous detection of influenza viruses A and B using real-time quantitative PCR. J. Clin. Microbiol. 2001;39:196–200. doi: 10.1128/JCM.39.1.196-200.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schweiger B., Zadow I., Heckler R., Timm H., Pauli G. Application of a fluorogenic PCR assay for typing and subtyping of influenza viruses in respiratory samples. J. Clin. Microbiol. 2000;38:1552–1558. doi: 10.1128/jcm.38.4.1552-1558.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Spackman E., Senne D.A., Myers T.J., Bulaga L.L., Garber P.L., Perdue M.L., Lohman K., Daum L.T., Suarez D.L. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian 5 and H7. J. Clin. Microbiol. 2002;40:3256–3260. doi: 10.1128/JCM.40.9.3256-3260.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rahman A., Fox J.D., Westmoreland D. Development and evaluation of NASBA and real-time RT-PCR for diagnosis of viral respiratory tract infections. J. Clin. Virol. 2000;18:174. (P200) [Google Scholar]
  • 27.Collins R.A., Ko L.-S., So K.-L., Ellis T., Lau L.-T., Yu A.C.H. Detection of highly pathogenic and low pathogenic avian influenza subtype H5 (Eurasian lineage) using NASBA. J. Virol. Methods. 2002;102:213–225. doi: 10.1016/s0166-0934(02)00034-4. [DOI] [PubMed] [Google Scholar]
  • 28.Shan S., Ko L.S., Collins R.A., Wu Z., Chen J., Chan K.Y., Xing J., Lau L.T., Yu A.C.H. Comparison of nucleic acid-based detection of avian influenza H5N1 with virus isolation. Biochem. Biophys. Res. Commun. 2003;302:377–383. doi: 10.1016/s0006-291x(03)00165-7. [DOI] [PubMed] [Google Scholar]
  • 29.Collins R.A., Ko L.-S., Fung K.-Y., Chan K.-Y., Xing J., Lau L.-T., Yu A.C.H. Rapid and sensitive detection of avian influenza virus subtype H7 using NASBA. Biochem. Biophys. Res. Commun. 2003;300:507–515. doi: 10.1016/s0006-291x(02)02896-6. [DOI] [PubMed] [Google Scholar]
  • 30.Deiman B., van Aarle P., Sillekens P. Characteristics and application of nucleic acid sequence-based amplification (NASBA) Mol. Biotechnol. 2002;20:163–179. doi: 10.1385/MB:20:2:163. [DOI] [PubMed] [Google Scholar]
  • 31.Compton J. Nucleic acid sequence-based amplification. Nature. 1991;350:91–92. doi: 10.1038/350091a0. [DOI] [PubMed] [Google Scholar]
  • 32.D.F. Palmer, W.R. Dowdle, M.T. Coleman, G.C. Schild, Advanced laboratory techniques for influenza diagnosis, U.S. Department of Health, Education, and Welfare, Immunology Series, Washington DC, 1975
  • 33.Karber G. 50% end-point calculation. Arch. Exp. Pathol. Phamak. 1931;162:480–483. [Google Scholar]
  • 34.Barrett T., Inglis S.C. Growth, purification and titration of influenza viruses. In: Mahy W.J., editor. Virology: A Practical Approach. IRL Press; Washington, DC: 1985. [Google Scholar]
  • 35.Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., Higgins D.G. The ClustalX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;24:4876–4882. doi: 10.1093/nar/25.24.4876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Collins R.A., Ko L.-S., Fung K.Y., Lau L.-T., Xing J., Yu A.C.H. A method to detect major serotypes of foot-and-mouth disease virus. Biochem. Biophys. Res. Commun. 2002;297:267–274. doi: 10.1016/s0006-291x(02)02178-2. [DOI] [PubMed] [Google Scholar]
  • 37.Wu S.J.L., Lee E.M., Putvatana R., Shurtlife R.N., Porter K.R., Suharyono W.S., Watts D.M., King C.C., Murphy G.S., Hayes C.G., Romano J.W. Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay. J. Clin. Microbiol. 2001;39:2794–2798. doi: 10.1128/JCM.39.8.2794-2798.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Romano J.W., van Gemen B., Kievits T. NASBA: a novel, isothermal detection technology for qualitative and quantitative HIV- RNA measurements. Clin. Lab. Med. 1996;16:89–103. [PubMed] [Google Scholar]
  • 39.Witt D.J., Kemper M., Stead A., Sillekens P., Ginocchio C.C., Espy M.J., Paya C.V., Smith T.F., Roeles F., Caliendo A.M. Analytical performance and clinical utility of a nucleic acid sequence-based amplification assay for detection of cytomegalovirus infection. J. Clin. Microbiol. 2000;38:3994–3999. doi: 10.1128/jcm.38.11.3994-3999.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical and Biophysical Research Communications are provided here courtesy of Elsevier

RESOURCES